Multiple silver linings in spite of a soft Q2 24
15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."
Pages
61
Language
English
Published on
15/05/24
You may also be interested by these reports :
03/03/26
Given the company’s more tangible operational normalisation and earlier-than-expected exit from the accelerated safeguard plan, incorporating ...
03/03/26
S&N delivered a healthy Q4 and broadly in-line FY25 performance, supported by recovery in Orthopaedics, strong Sports Medicine momentum, and ...
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...